Cat. No.: HY-174406A

MT-125 free base

Customer Review

Based on 1 Customer Validation

MT-125 free base is a specific and well-tolerated inhibitor of non-muscle myosin IIA (K_i,NMIIA = 2.7 μM) and IIB (EC₅₀ = 1.7 μM). MT-125 free base can pass through the blood-brain barrier. MT-125 free base induces ferroptosis and DNA damage by increasing the levels of reactive oxygen species (ROS) within tumor cells. MT-125 free base can enhance the PDGFR signaling pathway. MT-125 free base can be used for research on glioblastoma.

For research use only. We do not sell to patients.

Purity: 98.67%
CAS No.: 2404652-80-6
Formula: C₂₂H₁₉N₃O₂
Molecular Weight:357.41

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

MT-125 free base Chemical Structure

CAS No.: 2404652-80-6

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target^[1]

PDGFRα

All Myosin Isoforms :

MLCK

All PDGFR Isoforms :

All Akt Isoforms :

All mTOR Isoforms :

All ERK Isoforms :

In Vitro

MT-125 free base (5 μM, 8 h) significantly inhibits the invasive ability of one murine (MES1861) and three human (187, 190, and L1) Glioblastoma (GBM) cell lines^[1].
MT-125 free base (5 μM, 48 h) leads to 12 %-25 % cell multinucleation in 10 human GBM cells^[1].
MT-125 free base (0.1-10 μM; 96 h) produces over 90 % cytotoxicity in various mouse and human GBM cell lines^[1].
MT-125 increase reactive oxygen species (ROS) and lipid peroxidation levels in L1 cells^[1].
MT-125 free base (4 μM) can induce ferroptosis and ferroptosis inhibitors can reverse its cytotoxicity in Trp53(-/-) cells^[1].
MT-125 free base (5 μM, 48 h) significantly increase PDGFRα expression and activation of downstream signaling pathways in Trp53(-/-) cells^[1].
MT-125 free base (5 μM, 48 h) regulates the MAPK signaling pathway by inhibiting NMIIA in Trp53(-/-) cells^[1].
MT-125 free base (5 μM, 48 h) exhibits synergistic effects with carcinogenic kinase inhibitors in Trp53(-/-) cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

murine (TRP53(-/-), Pten(-/-), TRP53/Pten(-/-)) and human (L1, L0, GBM1A, 612, QNS120, QNS166, QNS315) GBM cell lines
Concentration:

3.3-7.3 μM
Incubation Time:

96 h
Result:

Significantly inhibited the GBM cell lines.

Western Blot Analysis^[1]

Cell Line:

Trp53(‒/‒) cells
Concentration:

5 μM
Incubation Time:

48 h
Result:

Effectively enhanced activation of PDGFRα, AKT, mTOR, ERK1/2, and SRC.

In Vivo

MT-125 free base (10 mg/kg; s.c.; once daily; for 2 weeks) demonstrates low toxicity in vivo for the C57BL/6 mice^[1].
MT-125 free base (20 mg/kg, s.c.; once daily; for 7 days) does not cause any adverse effects related to medication and does not affect age-related weight changes in the C57BL/6 mice^[1].
MT-125 free base (7.5, 15, or 30 mg/kg; s.c.; once daily; for 28 days) maintain good tolerability in repeated dose toxicology studies in the female rats^[1].
MT-125 free base (10 mg/kg; i.p.; once daily; for 4 weeks) synergizes with oncogenic kinase inhibitors and can significantly inhibit the growth of tumor cells in the C57BL/6 mice with Trp53(?/?) tumors^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice (8-10 weeks; 25-35 g)^[1]
Dosage:

10 mg/kg
Administration:

Subcutaneous injection (s.c.); once daily for 2 weeks
Result:

Had good tolerance and the weight and hematological indicators of mice were within normal range.

Animal Model:

C57BL/6 mice (8-10 weeks; 25-35 g)^[1]
Dosage:

20 mg/kg
Administration:

Subcutaneous injection (s.c.); once daily for 7 days
Result:

Maintained normal body weight and hematological parameters within the normal range in mice.

Animal Model:

Female rats (8-10 weeks; 25-35 g)^[1]
Dosage:

7.5, 15, or 30 mg/kg
Administration:

Subcutaneous injection (s.c.); once daily for 28 days
Result:

Did not cause any obvious or lasting adverse health effects.

Animal Model:

C57BL/6 mice with Trp53(‒/‒) tumors (8-10 weeks; 25-35 g)^[1]
Dosage:

10 mg/kg, co-incubation with Paxalisib (HY-19962)
Administration:

Intraperitoneal injection (i.p.); once daily for 4 weeks
Result:

Markedly reduced tumor size to an isolated nest of HA-positive cells and prolonged survival rate.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 2404652-80-6
Appearance Solid
Molecular Weight 357.41
Formula C₂₂H₁₉N₃O₂
Color Light yellow to yellow
SMILES

CC1=CC2=C(N=C(N(C3=CC4=C(N=C(C)C=C4)C=C3)CC5)[C@]5(O)C2=O)C=C1
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 33.33 mg/mL (93.25 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7979 mL

13.9895 mL

27.9791 mL

5 mM

0.5596 mL

2.7979 mL

5.5958 mL

10 mM

0.2798 mL

1.3990 mL

2.7979 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 3.33 mg/mL (9.32 mM); Clear solution

This protocol yields a clear solution of ≥ 3.33 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (33.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 3.33 mg/mL (9.32 mM); Clear solution

This protocol yields a clear solution of ≥ 3.33 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (33.3 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (285 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Kenchappa RS, et al. MT-125 inhibits non-muscle myosin IIA and IIB and prolongs survival in glioblastoma. Cell. 2025 Jun 3:S0092-8674(25)00569-0. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7979 mL	13.9895 mL	27.9791 mL	69.9477 mL
	5 mM	0.5596 mL	2.7979 mL	5.5958 mL	13.9895 mL
	10 mM	0.2798 mL	1.3990 mL	2.7979 mL	6.9948 mL
	15 mM	0.1865 mL	0.9326 mL	1.8653 mL	4.6632 mL
	20 mM	0.1399 mL	0.6995 mL	1.3990 mL	3.4974 mL
	25 mM	0.1119 mL	0.5596 mL	1.1192 mL	2.7979 mL
	30 mM	0.0933 mL	0.4663 mL	0.9326 mL	2.3316 mL
	40 mM	0.0699 mL	0.3497 mL	0.6995 mL	1.7487 mL
	50 mM	0.0560 mL	0.2798 mL	0.5596 mL	1.3990 mL
	60 mM	0.0466 mL	0.2332 mL	0.4663 mL	1.1658 mL
	80 mM	0.0350 mL	0.1749 mL	0.3497 mL	0.8743 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

MT-125 free base

Bioactive Compound Library Max

Bioactive Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

PI3K/Akt/mTOR Compound Library

Protein Tyrosine Kinase Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Ferroptosis Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Neuroprotective Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Osteogenesis Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Multi-Target Compound Library

Radioprotector Library

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

All Myosin Isoforms

All PDGFR Isoforms

All Akt Isoforms

All mTOR Isoforms

All ERK Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

MT-125 free base Related Classifications

HY-174406A Related Classifications